India Globalization Capital, Inc. (NYSE: IGC) Focuses on Building Phytocannabinoid-based Pharmaceutical Portfolio
Core operations transitioned to phytocannabinoid-based therapies Four trial candidates targeting chronic pain, Alzheimer’s and other conditions Unique approach combining existing therapies with cannabinoids India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments. Currently, the Maryland-based corporation has a pipeline of cannabis-based combination candidates under development to treat Alzheimer’s disease, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy. Supporting this effort, the company has put together a robust intellectual property (IP) portfolio. IGC intends nothing less than to become a leading specialty provider of phytocannabinoid-based pharmaceuticals and complimentary…







